Altimmune To Present Phase 2 RECLAIM Results For Pemvidutide In Alcohol Use Disorder At AASLD Liver Meeting; FDA End-Of-Phase 2 Meeting Set For December

First presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder (AUD)

Presentation to take place on Monday, November 9, 2026, at The Liver Meeting

Company scheduled to hold End-of-Phase 2 meeting with FDA in December

MORRISTOWN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 receptor agonist, in serious liver diseases, today announced that a late-breaking abstract featuring results from the RECLAIM Phase 2 trial evaluating pemvidutide in adults with moderate-to-severe alcohol use disorder (AUD) has been accepted as an oral presentation at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2026, taking place November 5-9, 2026, in Denver, Colorado.

This first presentation at an international scientific conference will feature key results from RECLAIM, a randomized, double-blind, placebo-controlled trial evaluating once-weekly pemvidutide 2.4 mg versus placebo over 24 weeks. In topline results announced in July 2026, pemvidutide achieved the trial’s primary endpoint of a statistically significant reduction in heavy drinking days (HDD) per week compared with placebo, and met key secondary endpoints validated by the U.S. Food and Drug Administration (FDA) as registrational endpoints, including reduction in World Health Organization (WHO) Risk Drinking Levels and zero HDD, with a generally favorable tolerability profile.

Late-breaking abstracts at The Liver Meeting are reserved for new, scientifically important findings from prospective large clinical studies or high-impact translational research that could not be completed before the regular abstract deadline.

Details of the late-breaking oral presentation are as follows:

• Abstract Title: Efficacy and Safety of Pemvidutide in the Treatment of Adults with Alcohol Use Disorder: Results from RECLAIM, a 24-Week Phase 2 Randomized Double-Blind Placebo-Controlled Trial
• Session: Late-Breaker Session 3
• Date/Time: Monday, November 9, 2026, 10:30 a.m. MT / 12:30 p.m. ET
• Presenter: Henry R. Kranzler, M.D. Professor of Psychiatry and Director of the Center for Studies of Addiction at the University of Pennsylvania’s Perelman School of Medicine

A copy of this presentation will be accessible on the Events section of the Altimmune website immediately following the late-breaker session.

Additionally, the Company is scheduled to meet with the FDA in December for an End-of-Phase 2 meeting to discuss the Phase 3 registrational program for pemvidutide in AUD.